. On page 263 of this issue, Hochreiter-Hufford et al. 4 show that the phagocytic pathway also contributes to myoblast fusion. Specifically, they find that the presence of cells dying by the process of apoptosis, and a receptor that recognizes these dying cells, potentiate myoblast fusion during muscle development, regeneration and repair*.
The phospholipid phosphatidylserine is normally present in the inner leaflet of the cell membrane, but serves as an 'eat me' signal when exposed on the outer leaflet in apoptotic cells (Fig. 1) . On phagocytic cells, BAI1, the seven-pass transmembrane receptor for phosphatidylserine, signals through the conserved ELMO/Dock180/Rac1 signalling pathway to regulate the downstream actin cytoskeleton network and promote engulfment of dying cells 5 .
In the fruitfly Drosophila, four transmembrane receptors mediate myoblast adhesion, which subsequently activates the ELMO/Myoblast city/Rac signalling module. (Myoblast city is the Drosophila version of Dock180.) At the site of myoblast-myoblast contact, this module remodels the actin cytoskeleton to drive fusion. The ELMO/Dock180/Rac1 module is conserved in zebrafish and mammals. In mammals, however, numerous receptors have been found that mediate myoblast-myoblast contact and adhesion between myoblasts and the developing myofibres called myotubes, with related and novel proteins continuing to be identified 1, 2 . It remains unclear how the different receptors contribute to and coordinate the fusion process.
Previous studies [6] [7] [8] have linked exposure of phosphatidylserine on myoblasts to the enhancement of fusion, yet the receptor mediating this signal has not been identified. Hochreiter-Hufford et al. asked whether BAI1 might transduce the phosphatidylserine signal during mammalian myoblast fusion. They find that the levels of this receptor increase during fusion in vitro, and that it is expressed in actively fusing myotubes in vivo. Moreover, increasing the expression of BAI1 enhanced fusion in an ELMO/Dock180/Rac1-dependent manner in vitro, indicating that the signalling pathway downstream of this receptor is intact (Fig. 1) .
The authors also report that BAI1 seems to be required for muscle development and repair in vivo. The muscles of mice lacking the Bai1 gene were fully formed but were smaller than those of control animals. And after injury, the regenerating muscles of the mutant mice remained smaller and contained fewer centrally localized nuclei; centrally positioned nuclei are a hallmark of muscle repair 9 . That muscles can still undergo some fusion in the absence of BAI1 suggests that the BAI1-related proteins BAI2 and/or BAI3, which are also expressed in muscle, may compensate for its loss. Contact between apoptotic cells and myotubes has been documented 4,7 during normal muscle development in vivo. HochreiterHufford and co-workers show that phospha tidylserine externalization, together with the activity of the caspase enzymes that mediate apoptosis, are necessary to enhance fusion. In agreement with previous work 10 , they find that inhibiting caspase activity using a pan-caspase inhibitor blocks fusion in vitro. Strikingly, the researchers could overcome this inhibition by adding apoptotic myoblasts, or even apoptotic thymocytes -unrelated cells belonging to the blood lineage. Thus, various types of apoptotic cell can provide a cue to healthy muscle cells to promote fusion.
Hochreiter-Hufford et al. did not observe fusion between apoptotic myoblasts and myotubes, whereas earlier work 7, 8 indicated that even non-apoptotic myoblasts show a feature of apoptosis, transiently externalizing phosphatidylserine before fusion. It could be that different cell populations contribute to fusion: fusion-capable myoblasts transiently expose . In muscle cells, however, this pathway does not lead to engulfment of apoptotic cells. But Hochreiter-Hufford et al. 4 report that phosphatidylserine-BAI1 signalling also enhances myoblast fusion -with healthy myoblasts and with the multinucleated myotubes -in an ELMO/Dock180/Rac1-dependent manner. The precise mechanism by which this occurs remains unclear, but it does not require fusion or engulfment of the apoptotic cell.
ne of the least-understood aspects of ageing is its coordinated and stereotyped progression in all organ systems. Although researchers have long suspected that the brain orchestrates systemic ageing, compelling evidence of this in mammals has been lacking. Furthermore, we have had no clear understanding of how ageing is affected by inflammation, which is a hallmark of age-related diseases such as diabetes, cardiovascular disease, arthritis and Alzheimer's disease. In this issue, Zhang et al. 1 (page 211) help to make this connection by documenting the integration of inflammatory responses with systemic control of ageing by the hypothalamus -a part of the brain that controls growth, reproduction and metabolism*.
Studies in invertebrate models of ageing, such as the nematode worm Caenorhabditis elegans 2,3 and the fruitfly Drosophila 4 , have suggested that nutrient-sensing and environmental-stress-sensing neurons can regulate ageing of the entire organism. Zhang and colleagues now propose that the hypothalamus, which has similar sensing functions in the mammalian brain, could also exert broad control over the physiological changes we call ageing. Their findings show that activity of the signalling molecule NF-κB increases in many regions of the brain in ageing mice, but that this increase is greatest in the hypothalamus. NF-κB is an important regulator of gene transcription that mediates immune-cell communication and inflammatory responses, and has been implicated previously in the control of gene expression during ageing 5 . Zhang and colleagues' work indicates that activation of NF-κB in microglia (cells in the brain that functionally resemble the macrophages of the immune system) stimulates secretion of the inflammatory cell-signalling molecule TNF-α, which, in turn, stimulates NF-κB signalling in hypothalamic neurons (Fig. 1) .
The authors go on to show that this feedforward loop leads to epigenetic changes (chemical and structural modifications that alter gene expression without changing the DNA sequence) in the gene that encodes gonadotropin-releasing hormone (GnRH), leading to its reduced expression. Moreover, their studies in mice suggest that reduced hypothalamic release of GnRH could contribute to several systemic attributes of ageing, including declining muscle strength, skin atrophy, bone loss, reduced neurogenesis and memory impairment. If validated, the results could have important implications for our understanding and treatment of agerelated diseases, particularly those linked to inflammation.
'Inflammageing' describes the close relationship between low-grade chronic inflammation and ageing that has been linked to a wide spectrum of age-related disorders in various organs, including the brain 6 . Healthy ageing and longevity could relate, in part, to reduced levels of inflammation or strong protective mechanisms that guard against adverse effects of chronic inflammation. Conversely, genetic and environmental factors that promote inflammation or disrupt the mechanisms involved in reducing inflammation seem to confer increased susceptibility to 'accelerated ageing' and age-related disorders such as insulin resistance, metabolic disorders phosphatidylserine without undergoing apoptosis; and dying myoblasts (and other cell types) enhance the fusion of healthy myoblasts without participating in fusion themselves. Indeed, as noted earlier, apoptotic mouse thymocytes, a cell type that does not fuse, could restore fusion in caspase-inhibited myoblasts. It is not clear how phosphatidylserine is presented by apoptotic cells and non-apoptotic cells so as to allow fusion of the latter but not of the former. Additional phosphatidylserinebinding proteins are required for myoblast fusion in vitro 11 , suggesting that phosphatidylserine may affect parallel, yet different, pathways during myoblast fusion.
If the apoptotic cells are not fusing with myotubes, how is the phosphatidylserine-BAI1 signal integrated with the other elements of the fusion machinery? It is likely that, in this case, BAI1 is not participating in the regulation of actin necessary for cell fusion, despite the fact that its influence on fusion depends on ELMO/Dock180/Rac1 signalling within the myotube. Because signalling by BAI1 can restore fusion capacity in caspase-inhibited myoblasts, which have decreased expression of several regulators of muscle-gene transcription 10 , this receptor may target genes essential for myoblast differentiation.
Transient externalization of phosphatidylserine has been observed in other cell-fusing systems -for instance, in trophoblast cells during placental development 12 . So the exposure of this phospholipid may be part of a conserved fusion mechanism. But is phosphatidylserine-BAI1 signalling common to all fusing systems? Moreover, apoptotic epithelial cells have previously been linked to compensatory proliferation and regeneration in a variety of organisms -from Hydra and planarians to Drosophila and mice 13 . It would be interesting to know whether phosphatidylserine-BAI1 signalling also induces proliferation and differentiation of satellite cells, the resident stem cells of skeletal muscle.
The present work provides a new dimension to the fields of myoblast fusion, muscle differentiation and muscle regeneration. A better understanding of the link between apoptosis, BAI1 signalling and fusion could lead to interventions that aid muscle recovery, be it after intense physical training or under conditions of disease-associated muscle wasting, prolonged bed rest or in the elderly. ■ Shannon F. Yu 
